[Clinical epidemiology of multiple sclerosis in Moscow. Сlinical demo-graphic characteristics in population of one region of Moscow]. / Klinicheskaia épidemiologiia rasseiannogo skleroza v Moskve. Sovremennye kliniko-demograficheskie osobennosti na primere populiatsii odnogo iz okrugov goroda.

The changes in clinical features of multiple sclerosis (MS) are noted worldwide which can be explained by diagnosis improvement and DMT implementation. Epidemiological studies of 2008-2012 in the North-West Administrative District of Moscow noted the higher proportion of women among patients of MS (M:F=1:2.61), longer duration of the disease (mean 14.3±10.6 years, maximum - 53 years) and life expectancy of patients (44.3±12.7 years, the maximum age - 77 years). The percentage of patients with secondary progressive course of MS increased (35%). In addition, MS onset before 16 years old was diagnosed more often (5.66% of cases) and late onset MS was identified in 4.04% of the cases. Up to 45.9% of MS patients have moderate and expressed disability (group 1 and 2 disability).

[Clinical epidemiology of multiple sclerosis in Moscow. Descriptive epidemiology in population of one region of Moscow].

The epidemiological study of multiple sclerosis (MS) has been done in the population (927 400 people) of the North-Western Administrative District (SZAO) of Moscow for the period of 2008-2012. In average for the 5 years the prevalence of MS was amounted to 53.38 cases per 100 000 population, incidence was 2.16 cases per 100 000 population and the mortality rate was 0.23 cases per 100 000 population. Thus, the population of SZAO belongs to high-incidence area. An increase in the prevalence of MS as well as a reduction of incidence and mortality were observed during a comparative analysis with the epidemiological indicators of MS in Moscow in the period of 1991-1996. Such dynamics of epidemiological indicators is due to the accumulation of patients in population that, in the first place, is related with the quality improvement of diagnostic and therapeutic-rehabilitative measures which increased the frequency of early diagnosis and patient's life expectancy together with the implementation of disease-modifying therapy (DMT) and modern methods of symptomatic treatment.

[Pregnancy and delivery in women with multiple sclerosis: a retrospective analysis].

We have analyzed the course of multiple sclerosis (MS) in 155 pregnant women. In 85.7% cases, pregnancy resulted in delivery and in 14.3% cases - in abortion. Patients presented with relapse very shortly after the abortion and received hormonal treatment. Patients treated with disease-modifying drugs (DMD) did not have relapses during pregnancy compared to those who did not receive DMD before the pregnancy. In the latter group, 33 (40.2%) patients presented with relapses during the I trimester. After the delivery, the relapses were noted in 31 (27.2%) patients during the first year. The maximal number of relapses was recorded to the 3rd month after the delivery (58.1%) with the gradual reduction to the end of the year (6th month - 29% and 12th month - 12.9%). Patients who did not receive DMD had more relapses to the 3rd and 6th months after delivery. In conclusion, the use of DMD before the pregnancy is an important factor for prevention of relapses during pregnancy and after delivery.

[The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis].

We summarized the 1-year experience of using the Russian Β-interferon-1b biosimilar (infibeta) in 123 patients including 65 patients with relapsing-remitting multiple sclerosis (RMS) and 58 patients with secondary progressive multiple sclerosis (SPMS). The significant decrease in the frequency of exacerbations per year was seen during the first year of treatment. We also noted the stabilization of the process of disability without the rise in EDSS scores in more than 50% of patients. Good tolerability comparable to that of the original drug was observed during the first year of treatment. There was no refusal from therapy with infibeta, which indicated sufficiently strong adherence to this type of treatment.